Ramelteon
- Generic Name
- Ramelteon
- Brand Names
- Rozerem
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 196597-26-9
- Unique Ingredient Identifier
- 901AS54I69
- Background
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
- Indication
用于失眠症，特别适用于治疗难以入睡型失眠症。
- Associated Conditions
- Insomnia
The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 120
- Registration Number
- NCT02691013
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 26
- Registration Number
- NCT02669082
- Locations
- 🇯🇵
Sangenjaya Neurology and Psychosomatic Clinic, Setagaya, Tokyo, Japan
🇯🇵Himorogi Kokorono Clinic, Shinjuku, Tokyo, Japan
🇯🇵Ishikawa Mental Clinic, Sapporo, Hokkaido, Japan
Ramelteon Prevention of Delirium - RCT
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02564939
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Effect of Ramelteon on Smoking Abstinence
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 140
- Registration Number
- NCT02560324
- Locations
- 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Ramelteon in the Prevention of Post-operative Delirium
- Conditions
- Cognitive DisordersDelayed Emergence From AnesthesiaDeliriumDelirium, Dementia, Amnestic, Cognitive Disorders
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 80
- Registration Number
- NCT02324153
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Duke University
- Target Recruit Count
- 75
- Registration Number
- NCT02156271
Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> - Transitional Survey From the Preceding Drug-use Survey -
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 236
- Registration Number
- NCT02153086
Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3339
- Registration Number
- NCT02058992
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Takeda
- Registration Number
- NCT01685151
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 535
- Registration Number
- NCT01677182
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.